Modern combined hormonal therapy in early postmenopause women
https://doi.org/10.15829/1728-8800-2012-4-42-51
Abstract
Aim. To study the effects of hormone replacement therapy (HRT) with a combination of estradiol and drospirenone on cardiometabolic risk levels and subclinical vascular pathology among women in early postmenopause.
Material and methods. In total, 84 women in early postmenopause, who had given informed consent and underwent a standard examination, were divided into two groups: Group I (with gynaecologist-confirmed indications for HRT with Angeliq (1 mg 17 β-estradiol and 2 mg drospirenone)) and Group II (no HRT). All participants underwent the assessment of metabolic parameters, visceral obesity, intima-media thickness (IMT) of common carotid arteries (CCA), arterial stiffness, and microcirculation (MC) status at baseline and 12 months later.
Results. HRT demonstrated beneficial effects on autonomic regulation, lipid metabolism, CCA IMT, and arterial stiffness. It was also associated with a reduction in visceral obesity, some antihypertensive effect, and an increase in the MC dilatation reserve in postmenopausal women.
Conclusion. Low-dose combined hormone therapy with drospirenone and estradiol could be recommended to a specific clinical group of women in early postmenopause.
About the Authors
V. B. Mychka
A. L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical Complex, Moscow
Russian Federation
Russian Federation
M. Yu. Kirillova
A. L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical Complex, Moscow
Russian Federation
Russian Federation
I. V. Kuznetsova
Russian Medical Academy of Post-diploma Education, Moscow
Russian Federation
Russian Federation
N. A. Voychenko
I. M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
A. A. Fedorovich
A. L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical Complex, Moscow
Russian Federation
Russian Federation
T. V. Balakhonova
A. L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical Complex, Moscow
Russian Federation
Russian Federation
Yu. V. Prokhorova
Moscow State MedicoStomatological University, Moscow
Russian Federation
Russian Federation
V. A. Vyshivanyuk
Moscow State MedicoStomatological University, Moscow
Russian Federation
Russian Federation
References
1. Mosca L, Benjamin EJ, Berra K, et al. A Guideline from the American Heart Association. Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women–2011 Update. Circulation 2011; 123: 1243–62.
2. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Climacteric 2012; 15(2): 105–14.
3. Suhih GT, Adamyan LV. The condition and the aspects of reproductive health in Russian population. Contemporarytechnologies in diagnostics and treatment of gynecological disorders. M.: Pantori 2007; p. 5–19 Russian (Сухих Г.Т., Адамян Л.В. Состояние и перспективы репродуктивного здоровья населения России. Современные технологии в диагностике и лечении гинекологических заболеваний. Под ред. В.И. Кулакова, Л.В. Адамян. М.: Пантори 2007; 5–19).
4. Rosano GМ, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric 2006; 9 (Suppl 1): 19–27.
5. Boggia J, Thijs L, Hansen TW, et al. Ambulatory Blood Pressure Monitoring in 9357 Subjects From 11 Populations Highlights Missed Opportunities for Cardiovascular Prevention in Women. Hypertension 2011; 57(3): 397–405.
6. Gast G-C M, Pop V JM, Samsioe GN, et al. Vasomotor menopausal symptoms are associated with increased risk of coronary heart disease. Menopause 2011; 18(2): 146–51.
7. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, et al. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women’s Health Across the Nation Heart Study. Circulation 2008; 118: 1234–40.
8. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308(5728): 1583–77.
9. Karas R, Clarkson TB. Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI timing is everything. Menopausal Medicine 2003;10: 8–12.
10. Borgelt-Hansen L. Oral contraceptives: an update on health benefits and risks. J Am Pharm Assoc 2001; 41(6): 875–86. 11. Hodges GJ, Sharp L, Clements RE et al. Influence of age, sex, and aerobic capacity on forearm and skin blood flow and vascular conductance. Eur J Appl Physiol 2010; 109: 1009–15.
11. Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of cardiovascular disease the Framingham study. Ann Intern Med 1976; 85: 447–52.
12. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Preven Rehabil 2011; 18 (6): 775–89.
13. Kvernmo HD, Stefanovska A, Bracic A, et al. Oscillations in the human cutaneous blood perfusion signal modified by endothelium-dependent and endothelium-independent vasodilators. Microvasc Res 1999; 57: 298–309.
14. Jonson JM, Kellog DL. Local thermal control of the human cutaneous circulation. J Appl Physiol 2010; 109: 1229–38.
15. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 16(6): 716–27.
16. White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006; 48(2): 243–53.
17. Preston R, White W, Pitt B, et al. Effects of drospirenone/17-β estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18: 797–804.
18. Preston RA, Norris PM, Alonso AB, et al. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 2007; 14: 408–41.
19. Elger W, Beier S., Pollow K, et al. Conception and pharmacodynamic profile of drospirenone. Steroids 2003; 68(10–13): 891–905.
20. Saranyaratana W, Sakondhavat C, Silaruks S, et al. Effect of hormone therapy on lipid profile in menopausal women. J Med Assoc Thai 2006; 89 Suppl 4: S37–41.
21. Sudhir K, Esler MD, Jennings GL, Komesaroff PA. Estrogen supplementation decreases norepinephrine-induced vasoconstriction and total body norepinephrine spillover in perimenopausal women. Hypertension 1997; 30: 1538–43.
22. Pinto S, Virdis A, Ghiadoni L, et al. Endogenous estrogen and acetylcholineinduced vasodilatation in normotensive women. Hypertension 1997; 29: 268–73.
23. Gilligan DM, Badar DM, Panza JA, et al. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90: 786–91.
24. Brooks-Asplund EM, Kenney WL. Chronic hormone replacement therapy does not alter resting or maximal skin blood flow. J Appl Physiol 1998; 85: 505-10.
25. Arildsson M, Asker CL, Salerud EG, Strömberg T. Skin capillary appearance and skin microvascular perfusion due to topical application of analgesia cream. Microvasc Res 2000; 59: 14–23.
26. Vuilleumitr P, Decosterd D, Maillard M, et al. Postischemic forearm skin reactive hyperemia is related to cardiovascular risk factors in a healthy female population. J Hypertension 2002; 20: 1753–7.
27. Kuznetsova IV, Mychka VB, Voichenko NA, et al. Cardiovascular diseases prevention in postmenopausal women. Menopause Selected papers of the 13th World Congress on Menopause Rome, June 8–11, 2011: 352–4.
28. Mychka VB, Kuznetsova IV, Yureneva SV, et al. Hormonal Replacing Therapy in Women with Menopausal Symptoms and Evaluation of the Effects on Cardiovascular System.«Gynecological Endocrinology 2012» Vol. XXXIV №1 2012; 257–9.
29. Tolstov SN, Salov IA, Mychka VB, et al. The main approaches in managing premenopause women. Russian journal of Cardiology 2011; 6: 98–104. Russian (Толстов С.Н., Салов И.А., Мычка В.Б. и др. Основные принципы ведения женщин в пременопаузе. Российский кардиологический журнал 2011; 6: 98–104).
Review
For citations:
Mychka V.B., Kirillova M.Yu., Kuznetsova I.V., Voychenko N.A., Fedorovich A.A., Balakhonova T.V., Prokhorova Yu.V., Vyshivanyuk V.A. Modern combined hormonal therapy in early postmenopause women. Cardiovascular Therapy and Prevention. 2012;11(4):42-51. (In Russ.) https://doi.org/10.15829/1728-8800-2012-4-42-51
Views:
969
Email this article 
